Jean-Jacques Bienaimé

Ex-CEO of BioMarin Pharmaceuticals

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Born

January 1, 1954 - 71 years ago

Economy Sector

Healthcare

Tenure

18 years 6 months (May 2005 - Nov 2023)

Previous Experience

Chairman, President and Chief Executive Officer of Genencor International, Inc.; Chairman, President and Chief Executive Officer of Sangstat Medical Corporation; Senior Vice President of Worldwide Marketing and Business Development at Rhône-Poulenc Rorer Pharmaceuticals; various roles at Genentech, Inc.

Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceuticals since 2005. With a solid background in biotechnology, he previously led Genencor and SangStat Medical Corporation, building his expertise in business development and product commercialization. His career began at Genentech, where he played a part in launching groundbreaking treatments for heart attacks. Under his leadership, BioMarin has focused on creating unique therapies for rare diseases, significantly impacting patient lives. Interestingly, his total compensation reached over $21 million in 2023, largely from stock vesting based on past performance. His insider trading activity revealed significant fluctuations in his wealth, reaching up to an impressive $69 million during a peak period in 2020 before stabilizing around $64 million recently. A member of several biotechnology boards, he is committed to advancing the industry, blending a wealth of knowledge with hands-on leadership to drive innovation in healthcare.

Year

2023

Total Compensation

$23.10M

Salary

$1.39M

Board Justification

The compensation philosophy is designed to attract and retain executive talent while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$1.67M

Board Justification

Mr. Bienaimé’s annual cash incentive for 2023 as if he had remained employed as CEO in recognition of Mr. Bienaimé’s 2023 contribution and in light of the fact that he served as CEO for most of the year.

Other

$508.00K

Board Justification

This includes various forms of compensation such as health benefits, security measures, and consulting fees following his retirement.

Restricted Stock

$19.53M(211.07K RSU)

Board Justification

The stock that vested in 2023 includes service-based RSUs and performance-based RSUs granted in prior years that were earned based on performance metrics over the applicable periods.

Performance Metrics

The performance metrics for the annual cash incentive included Managed Sales Revenue and Non-GAAP Income targets.

Alexander Hardy

CEO of BioMarin Pharmaceuticals

December 2023 - Present